{"id":724905,"date":"2023-01-23T07:08:02","date_gmt":"2023-01-23T12:08:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/"},"modified":"2023-01-23T07:08:02","modified_gmt":"2023-01-23T12:08:02","slug":"unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/","title":{"rendered":"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings"},"content":{"rendered":"<h2>\nData support UNI-494\u2019s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p>LOS ALTOS, Calif., Jan.  23, 2023  (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation\u2019s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023.<\/p>\n<p>The following data will be presented at the NFK\u2019s Spring Clinical Meeting:<\/p>\n<ul>\n<li>Results from three pre-clinical studies of UNI-494, evaluating the risk of drug\/drug interactions (DDI) will be presented in a poster titled, \u201cIn Vitro Drug Interaction Studies of UNI-494 Indicate Low Risk of Drug-Drug Interactions.\u201d<\/li>\n<li>Efficacy data from a study of UNI-494 in a bilateral renal ischemia perfusion (I\/R) model will be presented in a poster titled, \u201cUNI-494 Lowers Urine 2-microglobulin in Rats.\u201d<\/li>\n<li>Outcomes from a study that evaluated the medication weight of various phosphate binders to bind 1 gram of phosphorus will be presented in a poster titled \u201cBinder Weight to Bind 1 Gram of Phosphate.\u201d<\/li>\n<\/ul>\n<p>\u201cWe continue to build on the growing body of clinical evidence that supports the therapeutic potential of our two lead programs in kidney diseases and are delighted to be presenting these positive data before an audience of leading kidney disease experts,\u201d said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive Therapeutics. \u201cWith the recently announced results of our successful bioequivalence study of Renazorb compared to Fosrenol\u00ae, we expect to file a New Drug Application with the U.S. Food and Drug Administration (FDA) in mid-2023. These data provide further evidence of the benefits of Renazorb as a powerful phosphate binder and highlight its enhanced product profile, which is expected to improve medication compliance and, thereby, improve outcomes and quality-of-life for chronic kidney disease patients with hyperphosphatemia.\u201d<\/p>\n<p>\u201cWe are very encouraged by the UNI-494 data to be presented as it should underscore the prodrug\u2019s potential to be reno-protective and to have low risk of DDI, both of which are important findings for this product candidate as a promising therapeutic for acute kidney disease, a condition for which there are currently no FDA approved therapies,\u201d added Dr. Gupta.<\/p>\n<p align=\"justify\">Fosrenol is a registered trademark of Shire International Licensing BV.<\/p>\n<p align=\"justify\">\n        <strong>About\u00a0Unicycive Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.\u00a0For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S36m6aPSGQ9SWzBHhuJkbGJDUK56q-x-jO8uMuhuYNjRFbOsBlW4jrZnqhx3j2h1lZ5Njl0THDRbEYzfMC_EBA==\" rel=\"nofollow noopener\" target=\"_blank\">www.unicycive.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-looking statements<\/strong>\n      <\/p>\n<p align=\"justify\">Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;forecast,&#8221; &#8220;estimated&#8221; and &#8220;intend&#8221; or other similar terms or expressions that concern Unicycive&#8217;s expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive&#8217;s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled \u2018Risk Factors\u2019 in Unicycive\u2019s Annual Report on Form 10-K for the year ended December 31, 2021, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.<\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">ir@unicycive.com<br \/>(650) 900-5470<\/p>\n<p align=\"justify\">Anne Marie Fields<br \/>Stern Investor Relations <br \/>annemarie.fields@sternir.com<br \/>212-362-1200<\/p>\n<p align=\"justify\">SOURCE: Unicycive Therapeutics, Inc.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDBlZjc1N2MtMDUwMi00Mjk4LWE0NjAtOTU2Mjc0MmIzZmQwLTEyMjIzMTY=\/tiny\/Unicycive-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Data support UNI-494\u2019s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation\u2019s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023. The following data will be presented at the NFK\u2019s Spring Clinical Meeting: Results from three pre-clinical studies of UNI-494, evaluating the risk of drug\/drug interactions (DDI) will be presented in a poster titled, \u201cIn Vitro Drug Interaction Studies of UNI-494 Indicate Low Risk of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-724905","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Data support UNI-494\u2019s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation\u2019s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023. The following data will be presented at the NFK\u2019s Spring Clinical Meeting: Results from three pre-clinical studies of UNI-494, evaluating the risk of drug\/drug interactions (DDI) will be presented in a poster titled, \u201cIn Vitro Drug Interaction Studies of UNI-494 Indicate Low Risk of &hellip; Continue reading &quot;Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-23T12:08:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings\",\"datePublished\":\"2023-01-23T12:08:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/\"},\"wordCount\":779,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/\",\"name\":\"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=\",\"datePublished\":\"2023-01-23T12:08:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/","og_locale":"en_US","og_type":"article","og_title":"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings - Market Newsdesk","og_description":"Data support UNI-494\u2019s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemia LOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) &#8212; Unicycive Therapeutics, Inc.\u00a0(Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation\u2019s (NFK) upcoming Spring Clinical Meetings taking place in Austin, Texas from April 11-15, 2023. The following data will be presented at the NFK\u2019s Spring Clinical Meeting: Results from three pre-clinical studies of UNI-494, evaluating the risk of drug\/drug interactions (DDI) will be presented in a poster titled, \u201cIn Vitro Drug Interaction Studies of UNI-494 Indicate Low Risk of &hellip; Continue reading \"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-23T12:08:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings","datePublished":"2023-01-23T12:08:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/"},"wordCount":779,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/","name":"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=","datePublished":"2023-01-23T12:08:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNDMwMSM1MzY4MzE1IzIyMTA3NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-announces-acceptance-of-three-abstracts-for-presentation-at-the-national-kidney-foundations-spring-clinical-meetings\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation\u2019s Spring Clinical Meetings"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=724905"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/724905\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=724905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=724905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=724905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}